Related references
Note: Only part of the references are listed.Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Paul C. Cremer et al.
LANCET RHEUMATOLOGY (2021)
Genetic mechanisms of critical illness in COVID-19
Erola Pairo-Castineira et al.
NATURE (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clonal expansion and activation of tissue-resident memory-like T(H)17 cells expressing GM-CSF in the lungs of patients with severe COVID-19
Yu Zhao et al.
SCIENCE IMMUNOLOGY (2021)
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites et al.
SCIENCE IMMUNOLOGY (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION
L. Pupim et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis
Manu Shankar-Hari et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith et al.
BMJ OPEN (2021)
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Maximilian Ackermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Jonas Schulte-Schrepping et al.
CELL (2020)
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities
Puja Mehta et al.
LANCET RESPIRATORY MEDICINE (2020)
A minimal common outcome measure set for COVID-19 clinical research
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES (2020)
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
Zelalem Temesgen et al.
MAYO CLINIC PROCEEDINGS (2020)
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series
Andreas Stallmach et al.
CRITICAL CARE (2020)
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Giacomo De Luca et al.
LANCET RHEUMATOLOGY (2020)
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Miriam Merad et al.
NATURE REVIEWS IMMUNOLOGY (2020)
brms: An R Package for Bayesian Multilevel Models Using Stan
Paul-Christian Buerkner
JOURNAL OF STATISTICAL SOFTWARE (2017)
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
Rudragouda Channappanavar et al.
CELL HOST & MICROBE (2016)
Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis
Luca Piccoli et al.
NATURE COMMUNICATIONS (2015)
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells
Clare A. Notley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)